Aclaris Therapeutics, Inc.
ACRS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $3 | $2 | $1 | $9 |
| % Growth | 85.6% | 22.1% | -84.2% | – |
| Cost of Goods Sold | $1 | $2 | $1 | $9 |
| Gross Profit | $3 | -$0 | $1 | -$0 |
| % Margin | 83.7% | -4.1% | 65.2% | -1% |
| R&D Expenses | $13 | $11 | $12 | $9 |
| G&A Expenses | $5 | $5 | $6 | $5 |
| SG&A Expenses | $5 | $5 | $6 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $2 | $2 | $1 | $86 |
| Operating Expenses | $20 | $18 | $19 | $100 |
| Operating Income | -$17 | -$18 | -$18 | -$100 |
| % Margin | -519.8% | -1,035.9% | -1,242.9% | -1,082.1% |
| Other Income/Exp. Net | $3 | $3 | $3 | $3 |
| Pre-Tax Income | -$15 | -$15 | -$15 | -$97 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$15 | -$15 | -$15 | -$97 |
| % Margin | -443% | -868.3% | -1,036.8% | -1,048.2% |
| EPS | -0.12 | -0.13 | -0.12 | -1.01 |
| % Growth | 7.7% | -8.3% | 88.1% | – |
| EPS Diluted | -0.12 | -0.13 | -0.12 | -1.01 |
| Weighted Avg Shares Out | 123 | 123 | 122 | 95 |
| Weighted Avg Shares Out Dil | 123 | 123 | 122 | 95 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $2 | $2 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$14 | -$17 | -$18 | -$14 |
| % Margin | -436.6% | -945.1% | -1,213.5% | -151.2% |